ERBB2 and neoplasm: Truncating mutations were present in 28% of the cohort and were associated with age, grade, tumour size, oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative breast cancer (TNBC) classification (Table 2).